ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation (MOLTO)
A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination With Atezolizumab and Obinutuzumab in Richter Transformation of CLL
Sponsor: Niguarda Hospital
Listed as NCT04082897, this PHASE2 trial focuses on CLL Transformation and remains ongoing. Sponsored by Niguarda Hospital, it has been updated 12 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Jun 2024 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Apr 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Jun 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jun 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Niguarda Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alessandria, Italy , Bellinzona, Switzerland , Bergamo, Italy , Bologna, Italy , Brescia, Italy , Lucerne, Switzerland , Milan, Italy , Novara, Italy , Pavia, Italy , Roma, Italy and 3 more locations